Lv0
0 积分 2026-07-07 加入
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
2天前
已完结
Ifebemtinib plus garsorasib as first-line treatment for KRAS(G12C)-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
4天前
求助中
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
10天前
已完结
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
10天前
已完结
Control Groups in RCTs Supporting Approval of Drugs for Systemic Rheumatic Diseases, 2012-2022
18天前
已关闭
Characteristics of race/ethnicity in trials leading to anti‐rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration
18天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
20天前
已完结
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
1个月前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
1个月前
已完结
皖公网安备34019202002308
